List of Excipients in Branded Drug FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL

« Back to Dashboard

Generic Drugs Containing FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL

Company	Ingredient	NDC	Excipient
Walgreens company	fexofenadine hcl and pseudoephedrine hcl	0363-0049	ACETONE
Walgreens company	fexofenadine hcl and pseudoephedrine hcl	0363-0049	CELLULOSE ACETATE
Walgreens company	fexofenadine hcl and pseudoephedrine hcl	0363-0049	CELLULOSE, MICROCRYSTALLINE
Walgreens company	fexofenadine hcl and pseudoephedrine hcl	0363-0049	COPOVIDONE
Walgreens company	fexofenadine hcl and pseudoephedrine hcl	0363-0049	CROSCARMELLOSE SODIUM
Walgreens company	fexofenadine hcl and pseudoephedrine hcl	0363-0049	FD&C BLUE NO. 1 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL?

# Of NDCs	Excipient
7	ACETONE
7	CELLULOSE ACETATE
7	CELLULOSE, MICROCRYSTALLINE
7	COPOVIDONE
7	CROSCARMELLOSE SODIUM
7	FD&C BLUE NO. 1 ALUMINUM LAKE

Fexofenadine HCl and Pseudoephedrine HCl: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 29, 2026

Fexofenadine HCl/pseudoephedrine HCl is a mature oral combination with limited active patent protection but continued commercial value in allergy and nasal-congestion markets. The strongest opportunities are private-label extended-release products, optimized tablets, compliant OTC distribution, pediatric or multiparticulate formats, and differentiated packaging rather than new chemical-entity exclusivity. The main technical challenge is controlling pseudoephedrine release while preserving fexofenadine dissolution, stability, tablet robustness, and dose uniformity.

What product is protected by fexofenadine HCl and pseudoephedrine HCl patents?

The reference products are Allegra-D 12 Hour and Allegra-D 24 Hour, which combine the antihistamine fexofenadine hydrochloride with the nasal decongestant pseudoephedrine hydrochloride.

Product	Fexofenadine HCl	Pseudoephedrine HCl	Release profile	Primary commercial positioning
Allegra-D 12 Hour	60 mg	120 mg	Extended release	Twice-daily allergy and congestion relief
Allegra-D 24 Hour	180 mg	240 mg	Extended release	Once-daily allergy and congestion relief

The combination addresses two symptoms with separate pharmacology:

• Fexofenadine provides peripheral H1-antihistamine activity with limited central nervous system penetration.
• Pseudoephedrine produces systemic alpha-adrenergic vasoconstriction and reduces nasal congestion.
• The formulation must release pseudoephedrine over the intended 12- or 24-hour period without materially delaying fexofenadine release.

The original combination patents have expired or are no longer commercially meaningful as barriers to ordinary generic entry. Current product development should therefore focus on formulation execution, regulatory compliance, manufacturing economics, and channel access rather than reliance on composition-of-matter exclusivity.

When does fexofenadine-pseudoephedrine lose exclusivity?

The principal chemical patents for fexofenadine and pseudoephedrine are long expired. Fexofenadine was developed as the active metabolite of terfenadine and entered the U.S. market in the 1990s. Pseudoephedrine has been marketed for decades.

The relevant commercial exclusivity position is summarized below.

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Basic compound patents	Expired
Combination-product patents	Expired or commercially ineffective
Formulation patents	Historical protections have expired or do not prevent standard generic competition
Pediatric exclusivity	No current barrier to entry
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
OTC monograph exclusivity	Not a meaningful patent substitute for this mature combination

The FDA Orange Book remains the principal reference for approved NDA products and listed patent information. A current commercial assessment should distinguish between historical patent listings and patents capable of delaying approval or launch. For this combination, the market is best treated as off-patent from a product-development perspective (FDA, 2024a).

What patents protect Allegra-D and generic fexofenadine-pseudoephedrine products?

Historical protection centered on combination and controlled-release formulations rather than a durable new chemical entity.

Representative patent themes include:

1. Combination treatment of allergic rhinitis and nasal congestion.
2. Oral dosage forms containing fexofenadine and pseudoephedrine.
3. Controlled or sustained release of pseudoephedrine.
4. Matrix, multilayer, or coated-tablet systems.
5. Dosing regimens intended to provide antihistamine coverage with prolonged decongestant activity.

The most commercially important patent family associated with the Allegra platform included U.S. patents directed to fexofenadine and related formulations. Those rights were subject to historical ANDA litigation and settlement activity, but they are not a current obstacle to routine generic development.

A practical freedom-to-operate review should still examine:

• Active U.S. patents covering specific multilayer or osmotic delivery systems.
• Foreign patents with remaining term in markets where the product is not fully genericized.
• Patents on abuse-deterrent or tamper-resistant pseudoephedrine systems.
• Patent claims directed to pediatric multiparticulates or orally disintegrating dosage forms.
• Trade dress and trademark rights covering Allegra branding.

Trademark rights remain separate from patent rights. A generic can compete without infringing Allegra trademarks if it uses distinct product names, packaging, tablet markings, and labeling.

What formulation and excipient strategy is most effective?

The preferred commercial platform is an immediate-release fexofenadine layer combined with an extended-release pseudoephedrine matrix or coated fraction. A single homogeneous matrix can be used, but it increases the risk of dissolution tradeoffs between the two actives.

Recommended dosage-form architecture

Architecture	Technical advantages	Main risks	Commercial suitability
Bilayer tablet	Separates release functions; permits independent optimization	Compression, layer adhesion, weight variation	Strong for differentiated generic products
Coated extended-release tablet	Mature manufacturing platform; scalable	Coating uniformity and solvent or aqueous-process control	Strong
Matrix tablet	Simple process and lower unit cost	Risk of fexofenadine entrapment or pseudoephedrine dose dumping	Strong for cost-focused products
Multiparticulate capsule	Flexible release engineering; lower dose-dumping risk	Higher manufacturing and packaging cost	Useful for pediatric or premium products
Osmotic system	Predictable release profile	Higher development cost and device-like complexity	Selective opportunity
Immediate-release combination	Simple formulation	Does not reproduce 12- or 24-hour reference profile	Limited, unless separately approved

Excipient selection

Fexofenadine HCl is highly water soluble. The formulation objective is usually to avoid unnecessary retardation of fexofenadine while controlling pseudoephedrine release. Suitable excipient families include:

• Microcrystalline cellulose for compressibility and matrix structure.
• Lactose or mannitol for bulk and tablet mouthfeel, subject to moisture and compatibility assessment.
• Hypromellose of selected viscosity grades for hydrophilic matrix control.
• Ethylcellulose for a less water-soluble release-controlling barrier.
• Polyvinylpyrrolidone or hypromellose binders for granulation.
• Crospovidone or croscarmellose sodium where rapid fexofenadine disintegration is needed.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate or sodium stearyl fumarate for lubrication, with attention to over-lubrication.
• Opacifiers and film-coating polymers for light, moisture, and identification control.

The formulation should minimize excipient-driven changes in pseudoephedrine release under fed and fasted conditions. Hydrophilic matrices can show faster release in high-agitation or high-ionic-strength media. Polymer grade, particle size, compression force, tablet porosity, and coating weight gain should be treated as critical material and process variables.

Excipient risks

Pseudoephedrine HCl is a small, water-soluble salt. It can release rapidly from conventional matrices, creating dose-dumping risk if the matrix erodes too quickly or the coating is damaged. Key risks include:

• Alcohol-induced release acceleration.
• Mechanical failure during coating, packaging, or transport.
• Moisture uptake that changes tablet hardness or polymer hydration.
• Over-lubrication that slows wetting and alters dissolution.
• Chemical interaction between acidic or hygroscopic excipients and the active ingredients.
• Food-effect changes in gastric residence time and agitation.
• Inadequate discrimination between the reference product and comparator formulations during dissolution development.

A bilayer or coated-core approach generally provides more formulation control than a simple direct-compression matrix. The choice should be based on comparative dissolution, abuse-resistance requirements, manufacturing yield, and expected ANDA review risk.

What FDA regulatory pathway applies?

A conventional generic would generally use an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act if the reference product and dosage form are eligible for ANDA substitution.

The development package should address:

• Same active ingredients and strengths.
• Same dosage form and route of administration.
• Bioequivalence to the listed reference product.
• Extended-release performance over the full dosing interval.
• Comparative dissolution across multiple media and agitation conditions.
• Fed and fasted pharmacokinetic studies where required.
• Labeling and warning conformity.
• Stability through the proposed shelf life.
• Pseudoephedrine distribution and sales controls.

The FDA’s Orange Book identifies approved reference listed drugs and patent or exclusivity information. Product-specific guidance, where available, should be reviewed before committing to a bioequivalence design (FDA, 2024a; FDA, 2024b).

Pseudoephedrine creates a separate compliance burden. The Combat Methamphetamine Epidemic Act imposes retail sales limits, purchaser identification requirements, logbook or electronic-record requirements, and storage controls for products containing pseudoephedrine. State requirements can be stricter than federal requirements (U.S. Drug Enforcement Administration, 2024).

What is the Orange Book status of Allegra-D?

Allegra-D products were approved as prescription products before their OTC commercialization history and are now associated with over-the-counter allergy and congestion treatment. The commercially relevant question is whether an active Orange Book patent or exclusivity period prevents an ANDA or other generic pathway.

For a mature fexofenadine-pseudoephedrine product:

• New chemical entity exclusivity is not active.
• Historical formulation and combination patents do not create a current broad market block.
• Any proposed generic must confirm the current Orange Book entries for the exact reference product and strength.
• A Paragraph IV certification may be relevant only if an active listed patent remains for the target product.
• A Paragraph III certification could delay approval until patent expiration if an active listed patent is identified.

Because Orange Book listings can change, a launch decision must be tied to the FDA’s current product-specific records rather than historical patent summaries.

How many patents cover fexofenadine-pseudoephedrine products?

There is no commercially useful single count without defining the jurisdiction, product strength, patent family, and claim scope. Historical families covered the active ingredients, combination therapy, dosage forms, and controlled-release mechanisms. Many family members have expired, been abandoned, or lost practical relevance.

For business planning, the estate is best categorized as follows:

Patent category	Current generic-entry impact
Fexofenadine compound patents	None or negligible
Pseudoephedrine compound rights	None
Historical combination patents	Generally expired or nonblocking
Extended-release formulation patents	Must be checked claim by claim
Manufacturing-process patents	Usually design-aroundable
Packaging and anti-counterfeit patents	Product-specific
Trademark and trade dress	Relevant to branding, not generic approval

Patent strength is therefore moderate only for narrowly claimed, still-active delivery systems. It is weak for a standard bilayer, coated matrix, or conventional extended-release tablet that uses established excipient technology and does not copy a protected process.

What Paragraph IV challenges and litigation affect the market?

Historical ANDA litigation involving Allegra and fexofenadine products was tied to earlier patent terms and generic entry disputes. Those cases do not create a current broad barrier for a new entrant unless a specific active patent is listed against the selected reference product.

A new applicant should assess:

1. Whether the target NDA has an active patent listing.
2. Whether the proposed formulation practices any claim in that patent.
3. Whether a Paragraph IV certification is required.
4. Whether a 30-month stay could apply following a patent infringement action.
5. Whether a first-filer opportunity exists for any remaining listed patent.
6. Whether the proposed product can use a different release mechanism to support a Paragraph III or Paragraph I strategy.

The most defensible development position is usually a noninfringing formulation with a documented claim chart and a dissolution profile designed around the reference product, not a direct replication of its manufacturing process.

What generic entry risks exist?

The principal risks are regulatory and commercial rather than basic patent risk.

Regulatory risks

• Failure to match the reference product’s extended-release pharmacokinetics.
• Inadequate control of pseudoephedrine release under alcohol exposure.
• Failure to demonstrate acceptable fed-state performance.
• Difference in inactive ingredients that affects tolerability or bioequivalence.
• Inconsistent tablet strength, coating weight, or release profile.
• FDA questions about the suitability of the selected reference listed drug.

Commercial risks

• Retail restrictions on pseudoephedrine reduce impulse purchasing.
• Pharmacies may limit shelf space for products requiring behind-the-counter handling.
• Consumers may switch to intranasal decongestants, phenylephrine products, intranasal corticosteroids, or separate antihistamine and decongestant products.
• Retailers may favor established private-label suppliers with supply-chain reliability.
• Low generic pricing can compress margins despite strong unit demand.
• Seasonal demand creates inventory and working-capital risk.

A generic launch should prioritize supply reliability during peak allergy seasons and avoid dependence on one contract manufacturer or one coating line.

What commercial opportunities exist for excipient suppliers and manufacturers?

The product has several commercial opportunities despite its mature active-ingredient profile.

Private-label extended-release tablets

Retailers and pharmacy chains can market store-brand equivalents to Allegra-D 12 Hour and Allegra-D 24 Hour. The value proposition is lower acquisition cost with familiar active ingredients and a comparable release profile.

Premium formulation platforms

Manufacturers can differentiate through:

• Lower tablet size.
• Improved swallowability.
• Reduced friability.
• Lower moisture sensitivity.
• Alcohol-resistant release behavior.
• Improved packaging for bathroom and travel storage.
• Distinct 12-hour and 24-hour dosing formats.
• Multiparticulate capsules for patients with swallowing difficulty.

Any differentiated claim must be supported by regulatory evidence and should not imply superior clinical performance without appropriate data.

Excipient supplier opportunities

Excipient suppliers can support the market through:

• High-viscosity hypromellose grades for controlled release.
• Ethylcellulose systems for coating and matrix control.
• Co-processed direct-compression excipients.
• Low-moisture excipient grades.
• Functional film coatings.
• Lubricants optimized for extended-release tablets.
• Excipient systems with improved alcohol resistance.
• Technical service for scale-up and dissolution matching.

The strongest value is likely to come from excipient systems that improve process capability and reduce dissolution variability rather than from novel inactive ingredients alone.

Manufacturing and licensing opportunities

Potential commercial structures include:

• Contract development and manufacturing for regional private-label brands.
• Licensing of a validated extended-release platform.
• Supply agreements for coated pseudoephedrine particles.
• Dual-source manufacturing arrangements for seasonal demand.
• Regional licensing in markets where pseudoephedrine access differs from the U.S.
• Portfolio bundling with fexofenadine-only and pseudoephedrine-only products.

No biosimilar strategy applies because both actives are small molecules. The relevant competition is among ANDA-approved generics, OTC private labels, branded allergy products, and alternative decongestant delivery systems.

How does fexofenadine-pseudoephedrine compare with competing products?

Product category	Advantages	Limitations
Fexofenadine alone	Low sedation profile; broad allergy use	Does not directly relieve congestion
Fexofenadine/pseudoephedrine	Covers allergy symptoms and congestion	Pseudoephedrine cardiovascular and insomnia warnings; sales controls
Loratadine/pseudoephedrine	Established Claritin-D platform	Similar decongestant restrictions and generic competition
Cetirizine/pseudoephedrine	Strong antihistamine demand	More potential sedation for some users
Intranasal steroid plus antihistamine	Strong local nasal efficacy	Requires more complex regimen or device use
Phenylephrine combinations	Broad retail availability	Consumer and regulatory scrutiny regarding oral efficacy
Intranasal decongestants	Rapid local effect	Rebound congestion risk with prolonged use

The product’s commercial advantage is convenience for patients who need both antihistamine and decongestant treatment. Its main disadvantage is pseudoephedrine regulation and a narrower safety profile than fexofenadine alone.

What revenue exposure and market-entry scenarios should investors consider?

Manufacturers do not generally disclose Allegra-D revenue separately from broader allergy portfolios. Revenue modeling should therefore use scenario analysis rather than a reported product-level figure.

Scenario	Development profile	Expected commercial outcome
One low-cost generic	Standard extended-release tablet	Limited share but rapid retail acceptance
Two or more generic entrants	Conventional ANDA products	Price erosion and retailer-driven substitution
Private-label launch	Retailer-backed supply contract	Higher volume, lower unit margin
Premium differentiated formulation	Bilayer, smaller tablet, or multiparticulate	Potentially higher margin, slower adoption
Supply disruption at incumbent manufacturers	Reliable alternate supply	Temporary pricing and share opportunity
Seasonal demand spike	Prebuilt inventory and dual sourcing	Improved service level and retailer retention

The optimal launch strategy is usually a low-complexity, scalable formulation supported by strong supply planning. A highly novel formulation may be technically attractive but commercially inefficient if it requires a new clinical or regulatory pathway without meaningful consumer differentiation.

Key Takeaways

• Fexofenadine HCl/pseudoephedrine HCl is an off-patent, mature combination with continuing OTC demand.
• The main development opportunity is an ANDA-compatible extended-release tablet or capsule.
• A bilayer or coated-core design provides better independent control of fexofenadine and pseudoephedrine release than a simple homogeneous matrix.
• Hypromellose, ethylcellulose, functional coatings, and co-processed compression excipients are the most relevant excipient platforms.
• Current risks are centered on dissolution matching, alcohol resistance, pseudoephedrine controls, seasonal supply, and price erosion.
• Biosimilar risk is irrelevant; the competitive threat comes from generics, private labels, single-ingredient products, and alternative nasal therapies.
• Patent exposure should be confirmed against the current Orange Book entries for the exact Allegra-D reference product and strength.
• The best commercial opportunities are private-label supply, contract manufacturing, excipient platform licensing, and differentiated extended-release formats.

FAQs

Is fexofenadine-pseudoephedrine a good candidate for a generic launch?

Yes. The active ingredients are mature, the principal exclusivity barriers have expired, and demand is established. The launch case depends on achieving reliable extended-release bioequivalence and securing compliant pseudoephedrine distribution.

Which excipient is most important for controlling pseudoephedrine release?

The release-controlling polymer system is most important. Hypromellose matrices and ethylcellulose coatings are common starting platforms, but polymer viscosity, coating weight, tablet porosity, compression force, and particle size jointly determine performance.

Can a manufacturer avoid Allegra-D patent risk with a bilayer tablet?

A bilayer tablet can support a design-around strategy, but it does not automatically eliminate infringement risk. Patent claims must be compared with the exact composition, layer structure, release mechanism, and manufacturing steps.

Does pseudoephedrine require special packaging for OTC commercialization?

The product must comply with federal and state controls governing pseudoephedrine sales, recordkeeping, storage, and purchaser limits. Packaging and distribution plans should be designed for behind-the-counter or controlled retail handling.

Are fexofenadine-pseudoephedrine products subject to biosimilar competition?

No. Fexofenadine and pseudoephedrine are small-molecule drugs. Competition proceeds through generic-drug, OTC, private-label, and combination-product pathways rather than biosimilar regulation.

References

1. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (2024b). ANDA reference standards and product-specific guidance. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024c). DailyMed: Fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. U.S. Drug Enforcement Administration. (2024). Combat methamphetamine epidemic act requirements for retail sellers of scheduled listed chemical products. https://www.deadiversion.usdoj.gov/

5. U.S. Food and Drug Administration. (2024d). Nasal decongestant and antihistamine drug products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. Part 341. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341